Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Kobayashi Pharmaceutical Co stock price, quote, forecast and news

4967.T
JP3301100008
920477

Price

5,663.00
Today +/-
+0
Today %
+0 %
P

Kobayashi Pharmaceutical Co Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Kobayashi Pharmaceutical Co, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Kobayashi Pharmaceutical Co from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Kobayashi Pharmaceutical Co’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Kobayashi Pharmaceutical Co. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Kobayashi Pharmaceutical Co’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Kobayashi Pharmaceutical Co’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Kobayashi Pharmaceutical Co’s growth potential.

Kobayashi Pharmaceutical Co Revenue, EBIT and net profit per share

DateKobayashi Pharmaceutical Co RevenueKobayashi Pharmaceutical Co EBITKobayashi Pharmaceutical Co Net Income
2026e196.48 B undefined0 undefined21.13 B undefined
2025e188.16 B undefined0 undefined20.08 B undefined
2024e178.29 B undefined0 undefined17.34 B undefined
2023173.46 B undefined25.78 B undefined20.34 B undefined
2022166.26 B undefined26.67 B undefined20.02 B undefined
2021155.25 B undefined26.07 B undefined19.72 B undefined
2020150.51 B undefined25.94 B undefined19.21 B undefined
2019158.34 B undefined25.66 B undefined19.14 B undefined
2018167.48 B undefined26.29 B undefined18.02 B undefined
2017156.76 B undefined22.93 B undefined15.86 B undefined
2016120.05 B undefined17.41 B undefined14.32 B undefined
2015137.21 B undefined18.26 B undefined13.47 B undefined
2014128.34 B undefined17.92 B undefined12.45 B undefined
2013127.29 B undefined18.12 B undefined12.31 B undefined
2012121.53 B undefined16.9 B undefined12.18 B undefined
2011131.17 B undefined19.3 B undefined11.73 B undefined
2010130.82 B undefined18.63 B undefined9.34 B undefined
2009129.18 B undefined17.05 B undefined9.25 B undefined
2008125.69 B undefined15.83 B undefined8.85 B undefined
2007228.83 B undefined14.29 B undefined8.51 B undefined
2006257.02 B undefined14.44 B undefined8.3 B undefined
2005246.85 B undefined14.13 B undefined7.44 B undefined
2004215.71 B undefined13 B undefined6.69 B undefined

Kobayashi Pharmaceutical Co Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (B)EBIT (B)EBIT MARGIN (%)NET INCOME (B)NET INCOME GROWTH (%)DIV. ()DIV. GROWTH (%)SHARES (M)DOCUMENTS
1997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e
156.06166.59180.73185204.65210.92211.67215.71246.85257.02228.83125.69129.18130.82131.17121.53127.29128.34137.21120.05156.76167.48158.34150.51155.25166.26173.46178.29188.16196.48
-6.748.492.3610.623.070.351.9114.444.12-10.97-45.072.781.270.26-7.344.740.836.91-12.5130.586.84-5.46-4.943.157.094.332.785.544.42
28.8929.5031.7432.3630.5231.4832.2032.0731.1331.5633.6054.7655.7357.2858.3557.4357.4357.3758.0859.4960.9461.5757.4656.6557.1855.5355.56---
45.0949.1557.3659.8762.4666.3968.1569.1776.8581.1276.968.8371.9974.9476.5369.873.173.6379.6971.4195.52103.1290.9885.2788.7792.3396.38000
5.56811.2211.8410.6713.0713.941314.1314.4414.2915.8317.0518.6319.316.918.1217.9218.2617.4122.9326.2925.6625.9426.0726.6725.78000
3.564.806.216.405.226.206.586.035.725.626.2412.5913.2014.2414.7113.9114.2413.9613.3114.5014.6215.7016.2017.2416.7916.0414.86---
1.72.94.826.026.66.556.646.697.448.38.518.859.259.3411.7312.1812.3112.4513.4714.3215.8618.0219.1419.2119.7220.0220.3417.3420.0821.13
-71.3366.0524.829.57-0.701.310.7711.2011.592.514.094.470.9325.613.841.081.158.186.3510.7713.626.190.342.661.561.58-14.7515.825.19
------------------------------
------------------------------
85858585858584838383838282828282828281.4680.0778.9179.0778.4278.1678.1377.1375.84000
------------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Kobayashi Pharmaceutical Co Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Kobayashi Pharmaceutical Co is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Kobayashi Pharmaceutical Co provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Kobayashi Pharmaceutical Co's financial health and stability.

Assets

Kobayashi Pharmaceutical Co's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Kobayashi Pharmaceutical Co must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Kobayashi Pharmaceutical Co after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Kobayashi Pharmaceutical Co's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (B)DEPRECIATION (B)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (B)PAID INTEREST (M)PAID TAXES (B)NET CASH FLOW FROM OPERATING ACTIVITIES (B)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (B)CASH FLOW FROM OTHER INVESTING ACTIVITIES (B)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (B)NET CHANGE IN EQUITY (B)CASH FLOW FROM FINANCING ACTIVITIES (B)CASH FLOW FROM OTHER FINANCING ACTIVITIES (B)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (B)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
19992000200120022003200420052006200720082009201020112012201320142015null20162017201820192020202120222023
9.3911.4510.9212.8411.8312.7714.0116.0415.816.2714.5513.1819.8218.8519.6720.0618.7618.7619.822.5725.326.826.6427.6427.9527.56
1.972.223.233.483.353.243.413.373.764.214.264.163.232.973.13.13.073.072.633.523.44.134.114.845.366.06
00000000000000000000000000
-5,035-10,275-11,607-3,896-13,612-10,071-7,133-13,452-7,863-7,010-5,446-10,032-5,419-10,829-2,740-6,220-6,409-6,409-5,567-4,864-10,283-10,996-6,956-9,776-1,065-14,204
0.980.561.5-0.385.412.72.872.87-1.86-0.621.955.87-0.39-1.75-6.51-1.49-1.09-1.09-0.761.121.580.150.2-0.28-0.35-1.05
17111020213777869370631698347281891619192127261215171822
5.585.67.833.76.385.726.397.767.666.836.746.144.767.877.236.386.426.423.76.297.957.837.978.4688.36
7.313.964.0412.056.978.6313.168.839.8412.8515.3213.1717.259.2413.5115.4514.3314.3316.122.3520.0120.0923.9822.4231.8918.36
-3,629-4,213-3,601-2,793-1,862-4,578-2,285-1,947-2,628-2,791-2,985-2,165-2,092-2,875-3,344-3,678-4,047-4,047-3,485-3,205-3,701-4,804-4,149-4,185-16,229-13,569
-4.64-4.78-6.93-0.28-2.36-3.94-6.42-11.8-6.43-1.38-4.7-8.38-2.93-26.61-6.96-4.54-10.93-10.93-0.527.04-8.06-5.07-12.667.99-14.31-19.58
-1.01-0.57-3.332.52-0.50.64-4.13-9.86-3.81.41-1.71-6.21-0.84-23.73-3.62-0.86-6.89-6.892.9710.24-4.36-0.27-8.5112.181.92-6.01
00000000000000000000000000
-0.7-4.973.55-1.37-2.44-2.48-1.56-1.05-2.21-0.670.56-2.45-0.49-0.37-0.29-0.120.050.05-0.04-0.10.17-1.23-0.01-0.01-00
6.62-00-0.78-1.54-0.02-1.140.190.09-1.47-00-0-0-0-1.5-6.49-6.49-7.96-4.720.36-8.010-3.94-14.06-12
5.71-5.43.44-2.61-4.57-3.37-1.42-2.43-5.31-4.45-1.81-5.15-3.29-3.73-3.81-5.16-10.2-10.2-11.92-9.16-4.29-14.58-6.02-10.38-20.76-19.46
000.390.07-002.6500000-0.010-00.010.080.0800-0-0-0.23-0.17-0.19-0.24
-217-425-496-524-591-874-1,373-1,569-3,184-2,303-2,374-2,703-2,785-3,357-3,521-3,552-3,837-3,837-3,919-4,343-4,818-5,333-5,784-6,251-6,509-7,223
7.55-6.170.68.96-0.091.375.4-5.35-1.926.658.81-0.6610.87-20.513.586.5-6.97-6.972.920.377.230.364.8820.83-2.51-19.79
3,676-2514379,2535,1074,05610,8716,8877,20910,05712,33011,00115,1566,36810,16911,76710,282012,61219,14616,30515,28419,83518,23415,6634,791
00000000000000000000000000

Kobayashi Pharmaceutical Co stock margins

The Kobayashi Pharmaceutical Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Kobayashi Pharmaceutical Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Kobayashi Pharmaceutical Co.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Kobayashi Pharmaceutical Co's sales revenue. A higher gross margin percentage indicates that the Kobayashi Pharmaceutical Co retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Kobayashi Pharmaceutical Co's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Kobayashi Pharmaceutical Co's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Kobayashi Pharmaceutical Co's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Kobayashi Pharmaceutical Co. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Kobayashi Pharmaceutical Co's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Kobayashi Pharmaceutical Co Margin History

Kobayashi Pharmaceutical Co Gross marginKobayashi Pharmaceutical Co Profit marginKobayashi Pharmaceutical Co EBIT marginKobayashi Pharmaceutical Co Profit margin
2026e55.56 %0 %10.75 %
2025e55.56 %0 %10.67 %
2024e55.56 %0 %9.73 %
202355.56 %14.86 %11.73 %
202255.53 %16.04 %12.04 %
202157.18 %16.79 %12.7 %
202056.65 %17.24 %12.76 %
201957.46 %16.2 %12.09 %
201861.57 %15.7 %10.76 %
201760.94 %14.62 %10.12 %
201659.49 %14.5 %11.93 %
201558.08 %13.31 %9.81 %
201457.37 %13.96 %9.7 %
201357.43 %14.24 %9.67 %
201257.43 %13.91 %10.02 %
201158.35 %14.71 %8.94 %
201057.28 %14.24 %7.14 %
200955.73 %13.2 %7.16 %
200854.76 %12.59 %7.04 %
200733.6 %6.24 %3.72 %
200631.56 %5.62 %3.23 %
200531.13 %5.72 %3.01 %
200432.07 %6.03 %3.1 %

Kobayashi Pharmaceutical Co Stock Sales Revenue, EBIT, Earnings per Share

The Kobayashi Pharmaceutical Co earnings per share therefore indicates how much revenue Kobayashi Pharmaceutical Co has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Kobayashi Pharmaceutical Co earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Kobayashi Pharmaceutical Co's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Kobayashi Pharmaceutical Co’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Kobayashi Pharmaceutical Co's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Kobayashi Pharmaceutical Co Revenue, EBIT and net profit per share

DateKobayashi Pharmaceutical Co Sales per ShareKobayashi Pharmaceutical Co EBIT per shareKobayashi Pharmaceutical Co Earnings per Share
2026e2,643.08 undefined0 undefined284.17 undefined
2025e2,531.12 undefined0 undefined270.15 undefined
2024e2,398.27 undefined0 undefined233.25 undefined
20232,287.06 undefined339.92 undefined268.16 undefined
20222,155.5 undefined345.76 undefined259.58 undefined
20211,987.23 undefined333.63 undefined252.35 undefined
20201,925.64 undefined331.91 undefined245.7 undefined
20192,019.23 undefined327.2 undefined244.07 undefined
20182,118.24 undefined332.5 undefined227.95 undefined
20171,986.55 undefined290.52 undefined201.02 undefined
20161,499.31 undefined217.42 undefined178.85 undefined
20151,684.36 undefined224.15 undefined165.3 undefined
20141,565.17 undefined218.5 undefined151.8 undefined
20131,552.35 undefined221 undefined150.09 undefined
20121,482.1 undefined206.13 undefined148.49 undefined
20111,599.59 undefined235.34 undefined143 undefined
20101,595.41 undefined227.13 undefined113.84 undefined
20091,575.41 undefined207.91 undefined112.79 undefined
20081,532.84 undefined193.01 undefined107.96 undefined
20072,756.94 undefined172.17 undefined102.47 undefined
20063,096.65 undefined173.93 undefined99.96 undefined
20052,974.12 undefined170.22 undefined89.58 undefined
20042,598.89 undefined156.59 undefined80.55 undefined

Kobayashi Pharmaceutical Co business model

Kobayashi Pharmaceutical Co Ltd is a Japanese company that specializes in the production of health products. Kobayashi Pharmaceutical Co is one of the most popular companies on Eulerpool.com.

Kobayashi Pharmaceutical Co SWOT Analysis

Strengths

Kobayashi Pharmaceutical Co Ltd possesses several strengths that contribute to its competitive advantage in the market. Firstly, the company has a long-standing history and experience, which provides it with a strong foundation and reputation. This enhances customer trust and loyalty towards its products.

Additionally, Kobayashi Pharmaceutical Co Ltd has a diverse product portfolio that caters to a wide range of consumer needs. This helps the company to mitigate risks associated with dependence on a single product line and allows for revenue diversification.

Furthermore, the company boasts a strong research and development team that consistently delivers innovative products. This enables Kobayashi Pharmaceutical Co Ltd to stay ahead of competitors and adapt to changing market trends effectively.

Weaknesses

Despite its strengths, Kobayashi Pharmaceutical Co Ltd also faces certain weaknesses that can hinder its growth. One such weakness is its limited global market presence. The company primarily operates within the domestic market, limiting its potential for international expansion and reducing exposure to diverse customer bases.

Additionally, Kobayashi Pharmaceutical Co Ltd may face challenges in optimizing its supply chain and distribution network. These challenges can impact operational efficiency and lead to delays in reaching customers, potentially resulting in reduced customer satisfaction.

Opportunities

There are several opportunities for Kobayashi Pharmaceutical Co Ltd to capitalize on. Firstly, there is a growing global demand for health and wellness products, which aligns with the company's core offerings. By expanding its presence in international markets, Kobayashi Pharmaceutical Co Ltd can tap into this demand and drive revenue growth.

Furthermore, the company can explore strategic partnerships and collaborations with other healthcare organizations to enhance its product offerings or gain access to new markets. This can facilitate knowledge exchange and enable Kobayashi Pharmaceutical Co Ltd to leverage synergies in research and marketing efforts.

Threats

Despite the potential opportunities, Kobayashi Pharmaceutical Co Ltd must also be aware of potential threats. One major threat is intense competition within the pharmaceutical industry. The company operates in a highly competitive market where other players constantly introduce new products and innovations. This may impact market share and profitability.

Additionally, changing government regulations and policies can pose challenges to the company's operations. Compliance with evolving regulatory requirements may require substantial resources and could disrupt business processes if not managed effectively.

Kobayashi Pharmaceutical Co historical P/E ratio, EBIT, and P/S ratio.

Kobayashi Pharmaceutical Co shares outstanding

The number of shares was Kobayashi Pharmaceutical Co in 2023 — This indicates how many shares 75.842 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Kobayashi Pharmaceutical Co earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Kobayashi Pharmaceutical Co's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Kobayashi Pharmaceutical Co’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Kobayashi Pharmaceutical Co's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Kobayashi Pharmaceutical Co Stock splits

In Kobayashi Pharmaceutical Co's history, there have been no stock splits.

Kobayashi Pharmaceutical Co dividend history and estimates

In 2023, Kobayashi Pharmaceutical Co paid a dividend amounting to 101 JPY. Dividend means that Kobayashi Pharmaceutical Co distributes a portion of its profits to its owners.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details

Dividend

ⓘ

Dividend Overview

The dividend per year chart for Kobayashi Pharmaceutical Co provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify Kobayashi Pharmaceutical Co’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating Kobayashi Pharmaceutical Co's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

Kobayashi Pharmaceutical Co Dividend History

DateKobayashi Pharmaceutical Co Dividend
2026e107.81 undefined
2025e107.77 undefined
2024e107.79 undefined
2023101 undefined
202290 undefined
202183 undefined
202077 undefined
201973 undefined
201866 undefined
201758 undefined
201676 undefined
201547 undefined
201443.5 undefined
201343 undefined
201241 undefined
201134 undefined
201033 undefined
200929 undefined
200828 undefined
200738.5 undefined
200616.5 undefined
200510.5 undefined
200410.5 undefined

Kobayashi Pharmaceutical Co dividend payout ratio

In 2023, Kobayashi Pharmaceutical Co had a payout ratio of 32.97%. The payout ratio indicates the percentage of the company's profits that Kobayashi Pharmaceutical Co distributes as dividends.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Payout ratio
Details

Payout ratio

ⓘ

What is Yearly Payout Ratio?

The yearly payout ratio for Kobayashi Pharmaceutical Co represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.

How to Interpret the Data

A lower payout ratio for Kobayashi Pharmaceutical Co could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.

Using the Data for Investments

Evaluate Kobayashi Pharmaceutical Co's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.

Kobayashi Pharmaceutical Co Payout Ratio History

DateKobayashi Pharmaceutical Co Payout ratio
2026e33.4 %
2025e33.72 %
2024e33.51 %
202332.97 %
202234.67 %
202132.89 %
202031.34 %
201929.91 %
201828.95 %
201728.85 %
201642.49 %
201528.43 %
201428.66 %
201328.65 %
201227.61 %
201123.78 %
201028.99 %
200925.71 %
200825.94 %
200737.58 %
200616.51 %
200511.72 %
200413.04 %
Unfortunately, there are currently no price targets and forecasts available for Kobayashi Pharmaceutical Co.

Kobayashi Pharmaceutical Co latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
3/31/202454.95 13.13  (-76.1 %)2024 Q1
12/31/202357.11 64.52  (12.97 %)2023 Q4
9/30/202389.83 100.29  (11.65 %)2023 Q3
6/30/202351.84 55.92  (7.87 %)2023 Q2
3/31/202349.95 47.43  (-5.05 %)2023 Q1
12/31/202274.6 72.11  (-3.33 %)2022 Q4
9/30/202289.2 87.99  (-1.35 %)2022 Q3
6/30/202248.89 54.7  (11.87 %)2022 Q2
3/31/202247.53 44.87  (-5.6 %)2022 Q1
12/31/202163.4 61.94  (-2.3 %)2021 Q4
1
2
3

Eulerpool ESG Scorecard© for the Kobayashi Pharmaceutical Co stock

Eulerpool World ESG Rating (EESG©)

61/ 100

🌱 Environment

77

👫 Social

46

🏛️ Governance

61

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
❌
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
✅
Environmentally friendly packaging
✅
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
✅

Social

Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept✅
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting✅
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Kobayashi Pharmaceutical Co list of shareholders

%
Name
Stocks
Change
Date
8.07 % Kobayashi Foundation6,000,000012/31/2023
4.84 % MFS Investment Management3,597,900-1,009,60010/31/2022
3.13 % Watabe (Ikuko)2,325,000012/31/2023
2.79 % Forum Co., Ltd.2,071,000012/31/2023
2.53 % Nomura Asset Management Co., Ltd.1,879,31812,5003/31/2024
2.51 % Iue (Yukako)1,863,000012/31/2023
2.31 % The Vanguard Group, Inc.1,720,343-21,1003/31/2024
2.29 % KK Eko1,700,0001,700,00012/31/2023
2.07 % Miyata (Akihisa)1,540,000012/31/2023
12.46 % Kobayashi (Akihiro)9,264,000012/31/2023
1
2
3
4
5
...
10

Kobayashi Pharmaceutical Co Executives and Management Board

Mr. Kazumasa Kobayashi82
Kobayashi Pharmaceutical Co Chairman of the Board, Representative Director (since 1966)
Compensation 316 M
Mr. Akihiro Kobayashi51
Kobayashi Pharmaceutical Co President, Representative Director (since 2001)
Mr. Noriaki Hirao
Kobayashi Pharmaceutical Co Director of Finance & Accounting (since 2020)
Mr. Satoshi Yamane62
Kobayashi Pharmaceutical Co Senior Managing Director, Manager of CFO Unit, Chief Director of Main Office in Group Supervision (since 2006)
Mr. Naoki Ayabe
Kobayashi Pharmaceutical Co Managing Executive Officer, Chief Director of Main Sales Unit (since 2023)
1
2
3
4

Most common questions regarding Kobayashi Pharmaceutical Co

What values and corporate philosophy does Kobayashi Pharmaceutical Co represent?

Kobayashi Pharmaceutical Co Ltd is a renowned company that upholds strong values and an influential corporate philosophy. With a commitment to excellence, Kobayashi Pharmaceutical emphasizes innovation, research, and development to provide top-quality healthcare solutions. The company's core values revolve around customer satisfaction, integrity, and social responsibility. By consistently delivering trusted products, Kobayashi Pharmaceutical aims to improve the overall wellness and quality of life for individuals worldwide. With its dedicated team and progressive approach, Kobayashi Pharmaceutical Co Ltd continually strives to be a market leader in the pharmaceutical industry.

In which countries and regions is Kobayashi Pharmaceutical Co primarily present?

Kobayashi Pharmaceutical Co Ltd is primarily present in Japan. The company is a renowned pharmaceutical corporation based in Japan, known for its diverse range of healthcare and personal care products. With its headquarters in Tokyo, Kobayashi Pharmaceutical has established a strong presence and reputation in the domestic market. As a leader in the industry, the company continuously strives to provide innovative and high-quality solutions to improve the health and well-being of its consumers in Japan and beyond.

What significant milestones has the company Kobayashi Pharmaceutical Co achieved?

Kobayashi Pharmaceutical Co Ltd has achieved several significant milestones throughout its history. One notable achievement is the development of innovative healthcare products that cater to various consumer needs. The company has successfully introduced a wide range of over-the-counter drugs, personal care products, and medical devices to the market. Additionally, Kobayashi Pharmaceutical Co Ltd has expanded its global presence, establishing partnerships and subsidiaries in different countries. Its commitment to quality and research has earned the company a strong reputation in the industry. Overall, Kobayashi Pharmaceutical Co Ltd continues to make noteworthy progress in delivering trusted and reliable products to improve the well-being of its customers.

What is the history and background of the company Kobayashi Pharmaceutical Co?

Kobayashi Pharmaceutical Co Ltd is a renowned Japanese company that specializes in healthcare and personal care products. With a rich history dating back to its establishment in 1887, Kobayashi Pharmaceutical Co Ltd has become a trusted name in the industry. Over the years, the company has expanded its product portfolio and diversified into various sectors, including pharmaceuticals, cosmetics, and medical devices. With a commitment to innovation and quality, Kobayashi Pharmaceutical Co Ltd has successfully catered to the evolving needs of consumers. Today, it stands as a leading player in the global market, offering a wide range of high-quality products that enhance the health and well-being of individuals worldwide.

Who are the main competitors of Kobayashi Pharmaceutical Co in the market?

The main competitors of Kobayashi Pharmaceutical Co Ltd in the market include companies like Lion Corporation, Santen Pharmaceutical Co Ltd, and Takeda Pharmaceutical Company Limited. These competitors operate in various segments, such as personal care, eye care, and pharmaceuticals. Kobayashi Pharmaceutical Co Ltd faces tough competition from these companies in terms of market share, product offerings, and customer base. However, Kobayashi Pharmaceutical Co Ltd's strong brand reputation, innovative product portfolio, and commitment to quality help maintain its position as a key player in the industry.

In which industries is Kobayashi Pharmaceutical Co primarily active?

Kobayashi Pharmaceutical Co Ltd is primarily active in the healthcare industry.

What is the business model of Kobayashi Pharmaceutical Co?

The business model of Kobayashi Pharmaceutical Co Ltd is centered around the development, production, and sale of pharmaceutical and healthcare products. It focuses on providing innovative and high-quality solutions for various health issues. Kobayashi Pharmaceutical Co Ltd delivers a broad range of products, including over-the-counter drugs, dietary supplements, toiletries, and medical devices. With a commitment to research and development, the company strives to improve people's well-being globally. Kobayashi Pharmaceutical Co Ltd combines its expertise in both traditional and modern medicine to address the diverse needs of its customers. This company remains dedicated to promoting health and enhancing the quality of life through its comprehensive product portfolio.

What is the P/E ratio of Kobayashi Pharmaceutical Co 2024?

The Kobayashi Pharmaceutical Co P/E ratio is 24.77.

What is the P/S ratio of Kobayashi Pharmaceutical Co 2024?

The Kobayashi Pharmaceutical Co P/S ratio is 2.41.

What is the AlleAktien quality score of Kobayashi Pharmaceutical Co?

The AlleAktien quality score for Kobayashi Pharmaceutical Co is 3/10.

What is the revenue of Kobayashi Pharmaceutical Co 2024?

The expected Kobayashi Pharmaceutical Co revenue is 178.29 B JPY.

How high is the profit of Kobayashi Pharmaceutical Co 2024?

The expected Kobayashi Pharmaceutical Co profit is 17.34 B JPY.

What is the business model of Kobayashi Pharmaceutical Co

Kobayashi Pharmaceutical Co Ltd is a Japanese company that specializes in the manufacturing and distribution of health and beauty products. It has developed and brought to market a wide range of medical and cosmetic products since its founding in 1919, known for their high effectiveness and quality. The company's main division is pharmaceutical manufacturing, producing a variety of medicines for various diseases. The product range includes not only prescription medications, but also over-the-counter (OTC) products such as anti-inflammatory drugs, painkillers, and cough medicines. Kobayashi is also a major provider of eye drops and antibiotics and holds a leading position in the Japanese market for gastrointestinal drugs. Another important business sector for Kobayashi is the production of health and wellness products. The company offers a wide range of products, from multivitamin supplements and dietary supplements to weight loss products and anti-aging creams and skincare products. Kobayashi is particularly known for its high-quality patch products, which provide quick pain relief and healing for injuries. Kobayashi is also involved in the manufacturing of insect repellents and repellents. The company holds a leading position in the Japanese market for mosquito repellents and sprays and also offers products to protect against other insects such as fleas and ticks. In addition, Kobayashi has established a subsidiary, Kobayashi Create, which focuses on the development of performance and sports protective equipment. The company produces products such as knee pads and wrist guards, as well as compression clothing to help athletes prevent injuries and improve their performance. Kobayashi's business model is based on developing products that provide added value to customers. The company sees itself as a pioneer in the field of health and beauty products and therefore places great importance on research and development to offer its customers the best products on the market. Advanced market analysis helps the company better understand the needs and requirements of customers and develop more targeted products as a result. Kobayashi's global presence is steadily growing. The company operates in Europe, Asia, and North America, working closely with local partners to distribute its products worldwide and serve a wide range of customers. Kobayashi's strong market position and wide product range make it a key player in the global health market. In summary, Kobayashi Pharmaceutical Co Ltd is a successful company specializing in the development and manufacturing of high-quality health and beauty products. The company is committed to providing added value to its customers and places great importance on research, development, and market analysis to constantly develop new products and expand its range. With its global presence and strong market position, Kobayashi is an important player in the global health market.

What is the Kobayashi Pharmaceutical Co dividend?

Kobayashi Pharmaceutical Co pays a dividend of 90 JPY distributed over payouts per year.

How often does Kobayashi Pharmaceutical Co pay dividends?

The dividend cannot currently be calculated for Kobayashi Pharmaceutical Co or the company does not pay out a dividend.

What is the Kobayashi Pharmaceutical Co ISIN?

The ISIN of Kobayashi Pharmaceutical Co is JP3301100008.

What is the Kobayashi Pharmaceutical Co WKN?

The WKN of Kobayashi Pharmaceutical Co is 920477.

What is the Kobayashi Pharmaceutical Co ticker?

The ticker of Kobayashi Pharmaceutical Co is 4967.T.

How much dividend does Kobayashi Pharmaceutical Co pay?

Over the past 12 months, Kobayashi Pharmaceutical Co paid a dividend of 101 JPY . This corresponds to a dividend yield of about 1.78 %. For the coming 12 months, Kobayashi Pharmaceutical Co is expected to pay a dividend of 107.77 JPY.

What is the dividend yield of Kobayashi Pharmaceutical Co?

The current dividend yield of Kobayashi Pharmaceutical Co is 1.78 %.

When does Kobayashi Pharmaceutical Co pay dividends?

Kobayashi Pharmaceutical Co pays a quarterly dividend. This is distributed in the months of July, January, July, January.

How secure is the dividend of Kobayashi Pharmaceutical Co?

Kobayashi Pharmaceutical Co paid dividends every year for the past 23 years.

What is the dividend of Kobayashi Pharmaceutical Co?

For the upcoming 12 months, dividends amounting to 107.77 JPY are expected. This corresponds to a dividend yield of 1.9 %.

In which sector is Kobayashi Pharmaceutical Co located?

Kobayashi Pharmaceutical Co is assigned to the 'Non-cyclical consumption' sector.

Wann musste ich die Aktien von Kobayashi Pharmaceutical Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Kobayashi Pharmaceutical Co from 3/1/2025 amounting to 59 JPY, you needed to have the stock in your portfolio before the ex-date on 12/27/2024.

When did Kobayashi Pharmaceutical Co pay the last dividend?

The last dividend was paid out on 3/1/2025.

What was the dividend of Kobayashi Pharmaceutical Co in the year 2023?

In the year 2023, Kobayashi Pharmaceutical Co distributed 90 JPY as dividends.

In which currency does Kobayashi Pharmaceutical Co pay out the dividend?

The dividends of Kobayashi Pharmaceutical Co are distributed in JPY.

All fundamentals about Kobayashi Pharmaceutical Co

Our stock analysis for Kobayashi Pharmaceutical Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Kobayashi Pharmaceutical Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.